---
layout: post
title: "Human Gene Therapy Products Incorporating Human Genome Editing; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:58:28 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-05538
original_published: 2022-03-16 00:00:00 +0000
significance: 8.00
---

# Human Gene Therapy Products Incorporating Human Genome Editing; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** March 16, 2022 00:00 UTC
**Document Number:** 2022-05538

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled "Human Gene Therapy Products Incorporating Human Genome Editing; Draft Guidance for Industry." The draft guidance document provides recommendations to sponsors developing human gene therapy products incorporating genome editing (GE) of human somatic cells. Specifically, the guidance provides recommendations regarding information that should be provided in an investigational new drug (IND) application in order to assess the safety and quality of the investigational GE product, including information on product design, product manufacturing, product testing, preclinical safety assessment, and clinical trial design.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/03/16/2022-05538/human-gene-therapy-products-incorporating-human-genome-editing-draft-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2022-05538

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
